Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wally R Smith

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
The New England Journal of Medicine|December 14, 2016
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell DiseaseKenneth I Ataga, Abdullah Kutlar, Julie Kanter, et al.
American Journal of Hematology|September 29, 2011
Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodesCarlton D Dampier, Wally R Smith, Hae-Young Kim, et al.
American Journal of Preventive Medicine|June 21, 2016
Community Health Workers as Support for Sickle Cell CareLewis L Hsu, Nancy S Green, E Donnell Ivy, et al.
Clinical Trials (London, England)|March 30, 2013
IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studiesCarlton D Dampier, Wally R Smith, Carrie G Wager, et al.
British Journal of Haematology|October 6, 2021
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab studyDarla K Liles, Nirmish R Shah, Brigid Scullin, et al.
The New England Journal of Medicine|July 19, 2018
A Phase 3 Trial of l-Glutamine in Sickle Cell DiseaseYutaka Niihara, Scott T Miller, Julie Kanter, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
The New England Journal of Medicine|December 14, 2016
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell DiseaseKenneth I Ataga, Abdullah Kutlar, Julie Kanter, et al.
American Journal of Hematology|September 29, 2011
Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodesCarlton D Dampier, Wally R Smith, Hae-Young Kim, et al.
American Journal of Preventive Medicine|June 21, 2016
Community Health Workers as Support for Sickle Cell CareLewis L Hsu, Nancy S Green, E Donnell Ivy, et al.
Clinical Trials (London, England)|March 30, 2013
IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studiesCarlton D Dampier, Wally R Smith, Carrie G Wager, et al.
British Journal of Haematology|October 6, 2021
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab studyDarla K Liles, Nirmish R Shah, Brigid Scullin, et al.
The New England Journal of Medicine|July 19, 2018
A Phase 3 Trial of l-Glutamine in Sickle Cell DiseaseYutaka Niihara, Scott T Miller, Julie Kanter, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
Pageof 10